Macrocyclic peptide ligands developed via RaPID technology selectively bind and stabilize rhGBA1 in plasma at nanomolar concentrations without inhibiting endogenous GBA1, offering potential for combinatorial ERT-pharmacological chaperone for Gaucher disease. Here, GBA1 is linked to Gaucher disease.